Comparative analysis of mRNA and inactivated COVID-19 vaccines: A study from Faisalabad district of Pakistan

Munamm, Syed Ata Ul; Nadeem, Iftikhar; Mahdi, Noor; Saqlain, Muhammad; Rana, Zaid Khalid; Khatana, Usman Feroze; Bhatty, Umer Mustansir; Navayogaarajah, Visakan; Khan, Fatimah; Rasool, Masood Ur

doi:10.1177/14782715221131409

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a lack of VE data of two-dose inactivated vaccination for ischaemic stroke after SARS-CoV-2 infection. Therefore we decided to use the VE data of two-dose mRNA or viral vector vaccination because of their similar VE against severe COVID-19, critical COVID-19 and death due to COVID-19 [ 44 ].…”

Section: Methodsmentioning

confidence: 99%

Cost-Effectiveness Analysis of COVID-19 Inactivated Vaccines in Reducing the Economic Burden of Ischaemic Stroke after SARS-CoV-2 Infection

Qin

et al. 2023

Vaccines

View full text Add to dashboard Cite

Due to significant economic burden and disability from ischaemic stroke and the relationship between ischaemic stroke and SARS-CoV-2 infection, we aimed to explore the cost-effectiveness of the two-dose inactivated COVID-19 vaccination program in reducing the economic burden of ischaemic stroke after SARS-CoV-2 infection. We constructed a decision-analytic Markov model to compare the two-dose inactivated COVID-19 vaccination strategy to the no vaccination strategy using cohort simulation. We calculated incremental cost-effectiveness ratios (ICERs) to evaluate the cost-effectiveness and used number of the ischaemic stroke cases after SARS-CoV-2 infection and quality-adjusted life-years (QALYs) to assess effects. Both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis were performed to assess the robustness of the results. We found that the two-dose inactivated vaccination strategy reduced ischaemic stroke cases after SARS-CoV-2 infection by 80.89% (127/157) with a USD 1.09 million as vaccination program cost, saved USD 3675.69 million as direct health care costs and gained 26.56 million QALYs compared with no vaccination strategy among 100,000 COVID-19 patients (ICER < 0 per QALY gained). ICERs remained robust in sensitivity analysis. The proportion of older patients and the proportion of two-dose inactivated vaccination among older people were the critical factors that affected ICER. This study suggests the importance of COVID-19 vaccination is not only in preventing the spread of infectious diseases, but also in considering its long-term value in reducing the economic burden of non-communicable diseases such as ischaemic stroke after SARS-CoV-2 infection.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-Effectiveness Analysis of COVID-19 Inactivated Vaccines in Reducing the Economic Burden of Ischaemic Stroke after SARS-CoV-2 Infection

Qin

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

Safety and efficiency of COVID-19 vaccine in North Africa

Chelly,

Jaziri,

Ammar

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background In the absence of a specific treatment for COVID-19, preventive measures have been implemented to control this pandemic and vaccination is one of them. However, it is crucial to verify the safety and efficiency of every vaccine. The aim was to determinate the predictive factors of side effects and reinfection after COVID-19 vaccine. Methods A cross-sectional study was conducted in February 2022 among Tunisians infected with COVID-19 between March 2020 and February 2022, using an online self-administered questionnaire. We conducted univariate and multivariate analyses using binary stepwise logistic regression. Results A total of 1541 was selected from 1911 individuals. Comorbidities affected a quarter of the population (22.3%). Before the initial infection, 39.3% had received full vaccination, and 8.7% had received partial vaccination. By February 2022, the majority (82.9%) had received at least two vaccine doses. The reinfection rate was 30.6%. All vaccines prior to the first infection was identified as a protective factor against reinfection. Inactivated virus vaccinations were less likely to induce adverse effects. Conclusion ach vaccine has its own set of advantages and disadvantages: mRNA-based vaccines had a higher incidence of side effects but all vaccines provided better protection against reinfection.

show abstract

Leveraging Innovative Vaccines in Conquering Emerging Infectious Diseases

Kadir,

Prabhakar,

Ferdause

et al. 2024

Reshaping Healthcare With Cutting-Edge Biomedical Advancements

View full text Add to dashboard Cite

This chapter explores the role of innovative vaccines in combating emerging infectious diseases (EIDs). The rapid evolution of these diseases presents significant global health challenges, necessitating urgent investment in state-of-the-art vaccines. The chapter emphasizes the importance of proactive measures to mitigate these threats, contributing to improved healthcare and global public health. It provides a comprehensive overview of recent vaccine advancements, highlights the urgency of cutting-edge vaccines, and examines emerging vaccine technologies. It also presents case studies demonstrating vaccine impact and discusses strategies for proactive containment of EIDs. Technological advancements, such as mRNA and viral vector platforms, are explored, showcasing their potential to revolutionize vaccine production and response times. It outlines proactive strategies for EID containment, emphasizing the importance of research initiatives, global collaboration, and preparedness.

show abstract

Comparative analysis of mRNA and inactivated COVID-19 vaccines: A study from Faisalabad district of Pakistan

Cited by 3 publications

References 23 publications

Cost-Effectiveness Analysis of COVID-19 Inactivated Vaccines in Reducing the Economic Burden of Ischaemic Stroke after SARS-CoV-2 Infection

Cost-Effectiveness Analysis of COVID-19 Inactivated Vaccines in Reducing the Economic Burden of Ischaemic Stroke after SARS-CoV-2 Infection

Safety and efficiency of COVID-19 vaccine in North Africa

Leveraging Innovative Vaccines in Conquering Emerging Infectious Diseases

Contact Info

Product

Resources

About